PSA 2015 Snapshot: Pharma Experts Discuss Market Access for Breakthrough Medicines, What's Next?

In 2015, our annual Pharmaceutical Strategy Conference (PSA) hosted four pharmaceutical experts during our panel discussing market access and new payment methods for breakthrough medicines.Our panelists included:Garrett Ingram, VP, Head of US Market Access, SanofiSam Rasty, PhD, VP& Head of New Products, Rare Diseases Business Unit, Shire Pharmaceuticals in Lexington, Mass. Rod Cavin, Managing Director, Health Strategies Group. The company provides market access, insight and the market access research in the US and the U5 for pharmaceutical and device companies. Roger Longman, Chief Executive Officer, Real Endpoints. The company does objective drug valuation and pipeline products mostly for payers and pharmaceutical companies.Moderated by Casey McDonald, Senior Editor of Pharmaceutical ExecutiveSam Rastybegan the conversation with his views on gene and cell therapies and how they are relative to breakthrough medicines, their value to different stakeholders and emerging digital technologies.He first poses the question, what are some of these model payment mechanisms, etc.? Here was his response:There ’s the notion of gene therapy as being a single new approach but in reality, different gene therapeutics from a product development perspective I guess, have different product profiles. You’ve got non-viral, vector mediated delivery for gene therapy and viral. Within the viral component you’ve got multiple different viral vectors from a technical perspective th...
Source: ePharma Summit - Category: Pharmaceuticals Tags: drug pricing drugs medication Pharma pharma marketing pharmaceutical strategy pharmaceutical stratey conference PSA Source Type: blogs